The outcome in patients with BRAF‐mutated metastatic melanoma treated with anti‐programmed death receptor‐1 monotherapy or targeted therapy in the real‐world setting

The outcome in patients with BRAF‐mutated metastatic melanoma treated with anti‐programmed death receptor‐1 monotherapy or targeted therapy in the real‐world setting

Abstract Background Immunotherapy and targeted therapy are currently two alternative backbones in the therapy of BRAF‐mutated malignant melanoma. However, predictive biomarkers that would help with treatment selection are lacking. Methods This retrospective study investigated outcomes of anti‐progra...

Full description

Bibliographic Details
Main Authors: Jindřich Kopecký, Marek Pásek, Radek Lakomý, Bohuslav Melichar, Ivona Mrazová, Ondřej Kubeček, Monika Arenbergerová, Radmila Lemstrová, Alžběta Švancarová, Vojtěch Tretera, Alžběta Hlodáková, Kamila Žváčková
Format: Article
Language:English
Published: Wiley 2024-03-01
Series:Cancer Medicine
Subjects:
BRAF mutation
immunotherapy
real‐world data
targeted therapy
Online Access:https://doi.org/10.1002/cam4.6982

Internet

https://doi.org/10.1002/cam4.6982

Similar Items